PROCEPT BioRobotics announced the successful completion of three prostate cancer procedures using Aquablation therapy in an ambulatory surgery center (ASC) setting as part of the WATER IV Prostate Cancer trial. This marks the first time Aquablation, a robotic waterjet procedure for resecting prostate cancer, has been used in an ASC for this trial. The procedures, performed by Dr. Rahul Mehan, involved treating patients with localized prostate cancer (Grade Group 1 to 3) and resulted in same-day discharges without complications.
This development is important because it suggests that Aquablation therapy could offer a more efficient and cost-effective treatment option for prostate cancer. Moving procedures to an ASC setting potentially reduces healthcare costs compared to traditional hospital stays, expands patient access, and streamlines the treatment process. This is particularly relevant given the prevalence of prostate cancer and the increasing focus on value-based care.
The WATER IV PCa trial is designed to compare the safety and efficacy of Aquablation therapy to radical prostatectomy, the current standard of care for localized prostate cancer. The trial’s success in an ASC environment showcases Aquablation’s potential to shift the treatment paradigm. While most trial sites are hospital-based, the successful ASC procedures indicate the technology’s adaptability to different care settings.
This successful demonstration of Aquablation in an ASC setting could pave the way for broader adoption of this minimally invasive approach for prostate cancer treatment. It may lead to increased patient access to robotic surgery outside of traditional hospital settings, ultimately contributing to a more efficient and patient-centered approach to managing prostate cancer. Further data from the WATER IV trial will be crucial in solidifying the role of Aquablation in the treatment landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
